Joseph M. Manko Jr. was appointed as Class I director at MYOMO, INC..
“the Board appointed Joseph M. Manko Jr. to join the Board, effective on May 9, 2026.”
MYOMO, INC. — fact timeline
Source-grounded facts extracted from MYOMO, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MYOMO, INC. reported first quarter ended March 31, 2026 results: revenue $10,113,288, net income $3.0 million, EPS $0.07 per share. Guidance reaffirmed.
“Myomo Reports First Quarter 2026 Financial and Operating Results Revenue of $10.1 million with 49% of first quarter revenue from recurring patient sources MyoPro® orders received during the quarter were up 12% year-over-year Expanded gross margin, lower operating expenses and narrowed net loss Conference call begins at 4:30pm Eastern time today BURLINGTON, Mass. (May 7, 2026) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2026.”
MYOMO, INC. incurred term loan of up to $17.5 million with Avenue Capital Management II, L.P. (administrative agent) and Avenue Venture Opportunities Fund II, L.P. (lender) at the sum of 4.75% and the prime rate as reported in The Wall Street Journal maturing June 1, 2029.
“On November 4, 2025 (the “Closing Date”), Myomo, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan and Security Agreement”), with Avenue Capital Management II, L.P., as administrative agent and collateral agent (the “Agent”) and Avenue Venture Opportunities Fund II, L.P., as a lender (the “Lender”). Also on November 4, 2025, the Company entered into a Supplement to the Loan and Security Agreement (the “Supplement” and together with the Loan and Security Agreement, the “Loan Agreement”) with the Agent and the Lender. The Loan Agreement provides for committed term loans in an aggregate principal amount of up to $17.5 million with (a) $12.5 million funded on the Closing Date (“Tranche 1”) and (b) up to $5.0 million to be funded at any time between November 4, 2026 and May 4, 2027, so long as no default or event of default has occurred and is continuing.”
Yitzchak Jacobovitz departed as Director at MYOMO, INC..
“Also on April 4, 2025, Mr. Yitzchak Jacobovitz, a member of the Board and the Nominating and Corporate Governance Committee of the Board, informed the Company that he does not intend to stand for reelection at the Annual Meeting.”
Amy Knapp departed as Director at MYOMO, INC..
“On April 4, 2025, Ms. Amy Knapp, a member of the Board, the Audit Committee of the Board and the Nominating and Corporate Governance Committee of the Board, informed the Company that she does not intend to stand for reelection at the Company’s 2025 annual meeting of shareholders”
MYOMO, INC. reported first quarter ended March 31, 2024 results: revenue $3.8 million, net income $3.8 million, or $0.10 per share. Guidance raised.
“Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 8, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.